Innovative therapies for pediatric brain tumors

Current Opinion in Pediatrics

Volumn 11, Issue 1, 1999, Pages 39-46

  Rubin, Joshua B ^a   Kieran, Mark W ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; BROXURIDINE; CISPLATIN; ETANIDAZOLE; FUMAGILLOL CHLOROACETYLCARBAMATE; GANGLIOSIDE GM3; IODINE 125; IRIDIUM 192; LOBRADIMIL; METALLOPROTEINASE INHIBITOR; MISONIDAZOLE; MONOCLONAL ANTIBODY LM 609; PHENYLACETIC ACID; TEMOZOLOMIDE; TENASCIN; THALIDOMIDE; UNCLASSIFIED DRUG;

ANGIOGENESIS; BRACHYTHERAPY; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; DOSIMETRY; GENE THERAPY; HUMAN; IMMUNOTHERAPY; INFANT; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON RADIATION; REVIEW; STEREOTAXIC SURGERY;

BRAIN NEOPLASMS; CHILD; HUMANS;

EID: 0032992813     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199902000-00009     Document Type: Review

References (149)

1. Mickle, JP: Neurosurgery for pediatric brain tumors. Semin Pediatr Neurol 1997, 4:273-281. This paper is a general overview of neurosurgical issues related to the treatment of children with brain tumors.
2. Tomita T: Neurosurgical perspectives in pediatric neurooncology. Childs Nerv Syst 1998, 14:94-96. The authors emphasize the need for a presurgical, multidisciplinary approach to treatment planning in order to ensure optimal outcome.
3. Buatti JM, Meeks SL, Marcus RB Jr, Mendenhall NP: Radiotherapy for pediatric brain tumors. Semin Pediatr Neurol 1997, 4:304-319. Details treatment modalities and issues related to radiation therapy in children with brain tumors.
4. Kalapurakal JA, Thomas PR: Pediatric radiotherapy: an overview. Radiol Clin North Am 1997, 35:1265-1280. This paper reviews the application of radiation therapy for all cancers in children.
5. Robertson PL: Pediatric brain tumors. Prim Care 1998, 25:323-339. This is a comprehensive review of brain tumors in children including their classification and treatment.
6. Kadota RP: Perspectives on investigational chemotherapy and biologic therapy for childhood brain tumors. J Pediatr Hematol Oncol 1996, 18:13-22.
7. Allen JC, Siffert J: Contemporary issues in the management of childhood brain tumors. Curr Opin Neurol 1997, 10:137-141. This paper is a comprehensive overview of issues pertaining to the incidence, diagnosis, and treatment of pediatric brain tumors.
8. Kedar A: Chemotherapy for pediatric brain tumors. Semin Pediatr Neurol 1997, 4:320-332.
9. Ganslandt O, Steinmeier R, Kober H, Vieth J, Kassubek J, Romstöck J, et al.: Magnetic source imaging combined with image-guided frameless stereotaxy: a new method in surgery around the motor strip. Neurosurgery 1997, 41:621-627. Discussion. Neurosurgery 1997, 41:627-628.
10. Ganslandt O, Steinmeier R, Kober H, Vieth J, Kassubek J, Romstöck J, et al.: Magnetic source imaging combined with image-guided frameless stereotaxy: a new method in surgery around the motor strip. Neurosurgery 1997, 41:621-627. Discussion. Neurosurgery 1997, 41:627-628.
11. Rezai AR, Mogilner AY, Cappell J, Hund M, Llinás RR, Kelly PJ: Integration of functional brain mapping in image-guided neurosurgery. Acta Neurochir (Wien) 1997, 68(suppl):85-89.
12. Razai AR, Hund M, Kronberg E, Zonenshayn M, Cappell J, Ribary U, et al.: The interactive use of magnetooncephalography in stereotactic image-guided neurosurgery. Neurosurgery 1996, 39:92-102.
13. Patel N, Sandeman D: A simple trajectory guidance device that assists freehand and interactive image guided biopsy of small deep intracranial targets. Comput Aided Surg 1997, 2:186-192.
14. Schaller C, Meyer B, van Roost D, Schramm J: Image guided microsurgery with a semifreehand neuronavigational device. Comput Aided Surg 1997, 2:162-171.
15. Roessler K, Ungersboeck K, Aichholzer M, Dietrich W, Goerzer H, Matula C, et al.: Frameleas stereotactic lesion contour-guided surgery using a computer-navigated microscope. Surg Neurol 1998, 49:282-288. Discussion. Surg Neurol 1998, 49:288-289.
16. Roessler K, Ungersboeck K, Aichholzer M, Dietrich W, Goerzer H, Matula C, et al.: Frameleas stereotactic lesion contour-guided surgery using a computer-navigated microscope. Surg Neurol 1998, 49:282-288. Discussion. Surg Neurol 1998, 49:288-289.
17. Roessler K, Ungersboeck K, Dietrich W, Aichholzer M, Hittmeir K, Matula C, et al.: Frameless stereotactic guided neurosurgery: clinical experience with an infrared based pointer device navigation system. Acta Neurochir (Wien) 1997, 139:551-559.
18. Hata N, Dohi T, Iseki H, Takakura K: Development of a frameless and armless stereotactic neuronavigation system with ultrasonographic registration. Neurosurgery 1997, 41:608-613. Discussion. Neurosurgery 1997, 613-614.
19. Hata N, Dohi T, Iseki H, Takakura K: Development of a frameless and armless stereotactic neuronavigation system with ultrasonographic registration. Neurosurgery 1997, 41:608-613. Discussion. Neurosurgery 1997, 613-614.
20. McDermott MW, Gutin PH: Image-guided surgery for skull base neoplasms using the ISG viewing wand: anatomic and technical considerations. Neurosurg Clin North Am 1996, 7:285-295.
21. Saenz A, Zamorano L, Matter A, Bucius R, Diaz F: Interactive image guided surgery of the pineal region. Minim Invasive Neurosurg 1998, 41:27-30.
22. Kikinis R, Gleason PL, Moriarty TM, Moore MR, Alexander E, 3rd, Stieg PE, et al.: Computer-assisted interactive three-dimensional planning for neurosurgical procedures. Neurosurgery 1996, 38:640-649; discussion 649-651.
23. Kollias SS, Bernays R, Marugg RA, Romanowski B, Yonekawa Y, Valavanis A: Target definition and trajectory optimization for interactive MR-guided biopsies of brain tumors in an open configuration MRI system. J Magn Reson Imaging 1998, 8:143-159. This paper describes the process of MRI-guided neurosurgery.
24. Moriarty TM, Kikinis R, Jolesz FA, Black PM, Alexander E, 3rd: Magnetic resonance imaging therapy: intraoperative MR imaging. Neurosurg Clin N Am 1996, 7:323-331.
25. Tronnier VM, Wirtz CR, Knauth M, Lenz G, Pastyr O, Bonsanto MM, et al.: Intraoperative diagnostic and interventional magnetic resonance imaging in neurosurgery. Neurosurgery 1997, 40:891-900. Discussion. Neurosurgery 1997, 40:900-892. This is a review of intraoperative MRI.
26. Tronnier VM, Wirtz CR, Knauth M, Lenz G, Pastyr O, Bonsanto MM, et al.: Intraoperative diagnostic and interventional magnetic resonance imaging in neurosurgery. Neurosurgery 1997, 40:891-900. Discussion. Neurosurgery 1997, 40:900-892. This is a review of intraoperative MRI.
27. Laske DW, Morrison PF, Lieberman DM, Corthesy ME, Reynolds JC, Stewart Henney PA, et al.: Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg 1997, 87:586-594.
28. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, et al.: Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997, 41:44-46; discussion 48-49.
29. Sipos EP, Tyler B, Piantadosi S, Burger PC, Brem H: Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol 1997, 39:383-389.
30. Kong Q, Kleinschmidt Demasters, BK, Lillehei KO: Intralesionally implanted cisplatin cures primary brain tumor in rats. J Surg Oncol 1997, 64:268-273.
31. Williams JA, Dillehay LE, Tabassi K, Sipos E, Fahlman C, Brem H: Implantable biodegradable polymers for IUdR radiosensitization of experimental human malignant glioma. J Neurooncol 1997, 32:181-192.
32. Cardinale RM, Dillehay LE, Williams JA, Tabassi K, Brem H, Lee DJ: Effect of interstitial and/or systemic delivery of tirapazamine on the radiosensitivity of human glioblastoma multiforme in nude mice. Radiat Oncol Investig 1998, 6:63-70.
33. Goldman CK, Soroceanu L, Smith N, Gillespie GY, Shaw W, Burgess S, et al.: In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer. Nat Biotechnol 1997, 15:462-466. This paper demonstrates that agents other than just chemotherapeutic agents can be delivered by implantable wafers.
34. Matsumaru Y, Hyodo A, Nose T, Hirano T, Ohashi S: Embolic materials for endovascular treatment of cerebral lesions. J Biomater Sci Polym Ed 1997, 8:555-569.
35. Radcliffe J, Bennett D, Kazak AE, Foley B, Phillips PC: Adjustment in childhood brain tumor survival: child, mother, and teacher report. J Pediatr Psychol 1996, 21:529-539.
36. Freeman CR, Bourgouin PM, Sanford RA, Cohen ME, Friedman HS, Kun LE: Long term survivors of childhood brain stem gliomas treated with hyper-fractionated radiotherapy. Clinical characteristics and treatment related toxicities: the Pediatric Oncology Group. Cancer 1996, 77:555-562.
37. McDermott MW, Sneed PK, Gutin PH: Interstitial brachytherapy for malignant brain tumors. Semin Surg Oncol 1998, 14:79-87. This paper reviews the principles of brachytherapy and their clinical trials.
38. Sneed PK, Stauffer PR, McDermott MW, Diederich CJ, Lamborn KR, Prados MD, et al.: Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1996, 40:287-295.
39. Sneed PK, McDermott MW, Gutin PH: Interstitial brachytherapy procedures for brain tumors. Semin Surg Oncol 1997, 13:157-166.
40. Patchell RA, Yaes RJ, Beach L, Kryscio RJ, Davis DG, Tibbs PA, Young B: A phase I trial of neutron brachytherapy for the treatment of malignant gliomas. Br J Radiol 1997, 70:1162-1168.
41. Huncharek M: Meta-analytic re-evaluation of misonidazole in the treatment of high grade astrocytoma. Anticancer Res 1998, 18:1935-1939.
42. Chang EL, Loeffler JS, Riese NE, Wen PY, Alexander E, 3rd, Black PM, Coleman CN: Survival results from a phase I study of etanidazole [SR2508] and radiotherapy in patients with malignant glioma. Int J Radial Oncol Biol Phys 1998, 40:65-70.
43. Prados MD, Scott CB, Rotman M, Rubin P, Murray K, Sause W, et al.: Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1998, 40:653-659.
44. Glass J, Silverman CL, Axelrod R, Corn BW, Andrews DW: Fractionated stereotactic radiotherapy with cis-platinum radiosensitization in the treatment of recurrent, progressive, or persistent malignant astrocytoma. Am J Clin Oncol 1997, 20:226-229.
45. Shinoda J, Sakai N, Hara A, Ueda T, Sakai H, Nakatani K: Clinical trial of external-beam radiotherapy combined with daily administration of low-dose cisplatin for supratentorial glioblastoma multiforme: a pilot study. J Neurooncol 1997, 35:73-80.
46. Gridley DS, Archambeau JO, Andres MA, Mao XW, Wright K, Slater JM: Tumor necrosis factor-alpha enhances antitumor effects of radiation against glioma xenografts. Oncol Res 1997, 9:217-227.
47. Hua J, Olsson AR, Pero RW: Neutral metoclopramide sensitizes cytotoxicity induced by ionizing radiation in SCID mice xenografted with a human brain astrocytoma. Int J Cancer 1997, 73:871-874.
48. Botturi M, Fariselli L: Clinical results of unconventional fractionation radiotherapy in central nervous system tumors. Tumori 1998, 84:176-187.
49. Stuschke M, Thames HD: Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radial Oncol Biol Phys 1997, 37:259-267.
50. Murray KJ, Scott C, Greenberg HM, Emami B, Seider M, Vora NL, et al.: A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys 1997, 39:571-574.
51. Fallai C, Olmi P: Hyperfractionated and accelerated radiation therapy in central nervous system tumors (malignant gliomas, pediatric tumors, and brain metastases). Radiother Oncol 1997, 43:235-246.
52. McAllister B, Archambeau JO, Nguyen MC, Slater JD, Loredo L, Schulte R, et al.: Proton therapy for pediatric cranial tumors: preliminary report on treatment and disease-related morbidities. Int J Radiat Oncol Biol Phys 1997, 39:455-460. A summary of the results using a new radiation technique (proton therapy) for the treatment of patients with brain tumors with an emphasis on reduction of morbidity.
53. Miralbell R, Lomax A, Russo M: Potential role of proton therapy in the treatment of pediatric medulloblastoma/primitive neuro-ectodermal tumors: spinal theca irradiation. Int J Radiat Oncol Biol Phys 1997, 38:805-811.
54. Miralbell R, Lomax A, Bortfeld T, Rouzaud M, Carrie C: Potential role of proton therapy in the treatment of pediatric medulloblastoma/primitive neuroectodermal tumors: reduction of the supratentorial target volume. Int J Radiat Oncol Biol Phys 1997, 38:477-484. Discussion of a new and exciting radiation therapy technique that may significantly reduce toxicity.
55. Baumann GS, Wara WM, Larson DA, Sneed PK, Gutin PH, Ciricillo SF, et al.: Gamma knife radiosurgery in children. Pediatr Neurosurg 1996, 24:193-201.
56. Aggarwal R, Yeung D, Kumar P, Muhlbauer M, Kun LE: Efficacy and feasibility of stereotactic radiosurgery in the primary management of unfavorable pediatric ependymoma. Radiother Oncol 1997, 43:269-273.
57. Hacker FL, Kooy HM, Bellerive MR, Killoran JH, Leber ZH, Shrieve DC, et al.: Beam shaping for conformal fractionated stereotactic radiotherapy: a modeling study. Int J Radiat Oncol Biol Phys 1997, 38:1113-1121.
58. Bakardjiev AI, Barnes PD, Goumnerova LC, Black PM, Scott RM, Pomeroy SL, et al.: Magnetic resonance imaging changes after stereotactic radiation therapy for childhood low grade astrocytoma. Cancer 1996, 78:864-873.
59. Tarbell NJ, Loeffler JS: Recent trends in the radiotherapy of pediatric gliomas. J Neurooncol 1996, 28:233-244.
60. Barth RF, Soloway AH: Boron neutron capture therapy of brain tumors: current status and future prospects. J Neurooncol 1997, 33:3-7.
61. Soloway AH, Barth RF, Gahbauer RA, Blue TE, Goodman JH: The rationale and requirements for the development of boron neutron capture therapy of brain tumors. J Neurooncol 1997, 33:9-18. The authors describe the fundamentals of boron neutron capture therapy.
62. Chadha M, Capala J, Coderre JA, Elowitz EH, Iwai J, Joel DD, et al.: Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory. Int J Radiat Oncol Biol Phys 1998, 40:829-834.
63. Nakagawa Y, Hatanaka H: Boron neutron capture therapy: clinical brain tumor studies. J Neurooncol 1997, 33:105-115.
64. Yang W, Barth RF, Rotaru JH, Moeschberger ML, Joel DD, Nawrocky MM, et al.: Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of sodium borocaptate with or without blood-brain barrier disruption. Int J Radiat Oncol Biol Phys 1997, 37:663-672.
65. Buchholz TA, Laramore GE, Stelzer KJ, Risler R, Wootton P, Griffin TW: Boron neutron capture enhanced fast neutron radiotherapy for malignant gliomas and other tumors. J Neurooncol 1997, 33:171-178.
66. Coderre JA, Elowitz EH, Chadha M, Bergland R, Capala J, Joel DD, et al.: Boron neutron capture therapy for glioblastoma multiforme using p-boronophenylalanine and epithermal neutrons: trial design and early clinical results. J Neurooncol 1997, 33:141-152.
67. Ashley DM, Bigner DD: Recent advances in the biology of central nervous system tumors. Curr Opin Neurol 1997, 10:445-451. A detailed review of the neurobiology of brain tumors with an emphasis on potential targets for biologically based therapy.
68. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
69. Kuiper RA, Schellens JH, Blijham GH, Beijnen JH, Voest EE: Clinical research on antiangiogenic therapy. Pharmacol Res 1998, 37:1-16.
70. Zetter BR: Angiogenesis and tumor metastasis. Annu Rev Med 1998, 49:407-424. This paper discusses the relationship between a tumor's ability to promote angiogenesis and its metastatic potential.
71. Twardowski P, Gradishar WJ: Clinical trials of antiangiogenic agents. Curr Opin Oncol 1997, 9:584-589. The authors summarize the results of a number of clinical trials of several antiangiogenic factors.
72. Folkman J: Seminars in Medicine of the Beth Israel Hospital, Boston: clinical applications of research on angiogenesis [see comments]. N Engl J Mad 1995, 333:1757-1763.
73. Lund EL, Spang Thomsen M, Skovgaard Poulsen H, Kristjansen PE: Tumor angiogenesis: a new therapeutic target in gliomas. Acta Neurol Scand 1998, 97:52-62. This paper is a comprehensive review of the biology of angiogenesis, antiangiogenic factors, and their potential application to the treatment of CNS tumors.
74. Wesseling P, Ruiter DJ, Burger PC: Angiogenesis in brain tumors: pathobiological and clinical aspects. J Neurooncol 1997, 32:253-265.
75. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593-4599.
76. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, et al.: Flk-1 as a target for tumor growth inhibition. Cancer Res 1996, 56:3540-3545.
77. Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA: Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998, 92:391-400.
78. Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, et al.: Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 1998, 4:1101-1109.
79. Millar AW, Brown PD, Moore J, Galloway WA, Cornish AG, Lenehan TJ, Lynch KP: Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol 1998, 45:21-26.
80. Kudelka AP, Verschraegen CF, Loyer E: Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470 [letter]. N Engl J Med 1998, 338:991-992.
81. Dezube BJ, Von Roenn JH, Holden Wiltse J, Cheung TW, Remick SC, Cooley TP, et al.: Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol 1998, 16:1444-1449.
82. Herbst RS, Takeuchi H, Teicher BA: Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemother Pharmacol 1998, 41:497-504.
83. Phillips PH, Pluda JM, Cheson BD: Clinical trials referral resource: clinical trials using thalidomide. Oncology (Huntingt) 1996, 10:1498-1501.
84. Brandes AA, Scelzi E, Zampieri P, Rigon A, Rotilio A, Amista P, et al.: Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas. Am J Clin Oncol 1997, 20:364-367.
85. Kaba SE, DeMonte F, Bruner JM, Kyritsis AP, Jaeckle KA, Levin V, Yung WK: The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 1997, 40:271-275.
86. Chang SM, Barker FG, 2nd, Huhn SL, Nicholas MK, Page M, Rabbitt J, Prados MD: High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma. J Neurooncol 1998, 37:169-176.
87. Wu H, Beuerlein G, Nie Y, Smith H, Lee BA, Hensler M, et al.: Stepwise in vitro affinity maturation of Vitaxin, an alpha V beta3-specific humanized mAb. Proc Natl Acad Sci U S A 1998, 95:6037-6042.
88. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al.: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [see comments]. Cell 1994, 79:315-328.
89. Black WR, Agner RC: Tumour regression after endostatin therapy [letter]. Nature 1998, 391:450.
90. Harris AL: Are angiostatin and endostatin cures for cancer? Lancet 1998, 351:1598-1599.
91. Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [see comments]. Nature 1997, 390:404-407.
92. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
93. Klohs WD, Fry DW, Kraker AJ: Inhibitors of tyrosine kinase. Curr Opin Oncol 1997, 9:562-568.
94. Mackie EJ: Molecules in focus: tenascin-C. Int J Biochem Cell Biol 1997, 29:1133-1137. This paper provides a comprehensive review of one of the targets of monoclonal antibody therapy.
95. Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, et al.: Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol 1998,16:2202-2212.
96. Samid D, Hudgins WR, Shack S, Liu L, Prasanna P, Myers CE: Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. Adv Exp Med Biol 1997, 400A:501-505.
97. Prados MD, Russo C: Chemotherapy of brain tumors. Semin Surg Oncol 1998, 14:86-95.
98. Pech IV, Peterson K, Cairncross JG: Chemotherapy for brain tumors. Oncology 1998, 12:537-543, 547. Discussion. Oncology 1998, 12:547-538, 553. This paper is a good overview of chemotherapeutic options for pediatric patients with brain tumors.
99. Pech IV, Peterson K, Cairncross JG: Chemotherapy for brain tumors. Oncology 1998, 12:537-543, 547. Discussion. Oncology 1998, 12:547-538, 553. This paper is a good overview of chemotherapeutic options for pediatric patients with brain tumors.
100. National Cancer Institute: Current clinical trials. Oncology 1998, 5:115-128.
101. Kroll RA, Neuwelt EA: Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998, 42:1083-1099; discussion 1099-1100. This paper reviews the biology of the blood-brain barrier and describes several techniques for its disruption to increase the delivery of chemotherapeutic agents to the tumor.
102. Black KL, Cloughesy T, Huang SC, Gobin YP, Zhou Y, Grous J, et al.: Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J Neurosurg 1997, 86:603-609.
103. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C: Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997, 23:35-61.
104. Wright J, Ho PT, Phillips PH, Cheson BD: Clinical Trials: referral resource clinical trials using Cl-980 (mivobulin isethionate). Oncology 1997, 11:643-644.
105. Sklarin NT, Lathia CD, Benson L, Grove WR, Thomas S, Roca J, et al.: A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors. Invest New Drugs 1997, 15:235-246.
106. Hochberg F, Prados M, Russell C, Weissman D, Evans R, Cook P, et al.: Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation: a phase I-II study. J Neurooncol 1997, 32:45-55.
107. Holm B, Sehested M, Jensen PB: Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide. Clin Cancer Res 1998, 4:1367-1373.
108. Graham ML, Herndon JE 2nd, Casey JR, Chaffee S, Ciocci GH, Krischer JP, et al.: High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 1997, 15:1814-1823.
109. Jakacki RI, Jamison C, Heifetz SA, Caldemeyer K, Hanna M, Sender L: Feasibility of sequential high-dose chemotherapy and peripheral blood stem cell support for pediatric central nervous system malignancies. Med Pediatr Oncol 1997, 29:553-559.
110. Mason WP, Grovas A, Halpern S, Dunkel IJ, Garvin J, Heller G, et al.: Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998, 16:210-221.
111. Dunkel U, Boyett JM, Yates A, Rosenblum M, Garvin JH, Jr., Bostrom BC, et al.: High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group. J Clin Oncol 1998, 16:222-228.
112. Dunkel IJ, Garvin JH Jr, Goldman S, Ettinger U, Kaplan AM, Cairo M, et al.: High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. Children's Cancer Group. J Neurooncol 1998, 37:67-73.
113. Mason WP, Goldman S, Yates AJ, Boyett J, Li H, Finlay JL: Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma: a report of the Children's Cancer Group. J Neurooncol 1998, 37:135-143.
114. Guruangan S, Dunkel IJ, Goldman S, Garvin JH, Rosenblum M, Boyett JM, et al.: Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol 1998, 16:2486-2493.
115. Culver KW: Gene therapy for malignant neoplasms of the CNS. Bone Marrow Transplant 1996, 18 (suppl 3):S6-9.
116. Chung RY, Chiocca EA: Gene therapy for tumors of the central nervous system. Surg Oncol Clin N Am 1998, 7:589-602.
117. Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, et al.: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells [see comments]. Nat Med 1997, 3:1354-1361. This describes the novel technique of intratumoral implantation of vector-producing cells for gene therapy.
118. Andreansky S, He B, van Cott J, McGhee J, Markert JM, Gillespie GY. et al.: Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 1998, 5:121-130.
119. Tamura M, Shimizu K, Yamada M, Miyao Y, Hayakawa T, Ikenaka K: Targeted killing of migrating glioma cells by injection of HTK-modified glioma cells. Hum Gene Ther 1997, 8:381-391.
120. Kruse CA, Roper MD, Kleinschmidt DeMasters BK, Banuelos SJ, Smiley WR, Robbins JM, Burrows FJ: Purified herpes simplex thymidine kinase retrovector particles: I: in vitro characterization, in situ transduction efficiency, and histopathological analyses of gene therapy-treated brain tumors. Cancer Gene Ther 1997, 4:113-128.
121. Hsiao M, Tee V, Carmel J, Tsai Y, Feigner PL, Haas M, Silverberg GD: Intracavitary liposome-mediated p53 gene transfer into glioblastoma with endogenous wild-type p53 in vivo results in tumor suppression and long-term survival. Biochem Biophys Res Commun 1997, 233:359-364.
122. Badie B, Kramar MH, Lau R, Boothman DA, Economou JS, Black KL: Adenovirus-mediated p53 gene delivery potentiates the radiation-induced growth inhibition of experimental brain tumors. J Neurooncol 1998, 37:217-222.
123. Kondo S, Tanaka Y, Kondo Y, Ishizaka Y, Hitomi M, Haqqi T, et al.: Retroviral transfer of CPP32beta gene into malignant gliomas in vitro and in vivo. Cancer Res 1998, 58:962-967.
124. Cheney IW, Johnson DE, Vaillancourt MT, Avanzini J, Morimoto A, Demers GW, Wills KN, et al.: Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res 1998, 58:2331-2334.
125. Yu JS, Burwick JA, Dranoff G, Breakefield XO: Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther 1997, 8:1065-1072.
126. Tseng SH, Hwang LH, Lin SM: Induction of antitumor immunity by intracerebrally implanted rat C6 glioma cells genetically engineered to secrete cytokines. J Immunother 1997, 20:334-342.
127. Davis BM, Reese JS, KoÇ ON, Lee K, Schupp JE, Gerson SL: Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis[2-chloroethyl]-1-nitrosourea. Cancer Res 1997, 57:5093-5099.
128. Hesdorffer C, Ayello J, Ward M, Kaubisch A, Vahdat L, Balmaceda C, et al.: Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 1998, 16:165-172.
129. Cirielli C, Capogrossi MC, Passaniti A: Anti-tumor gene therapy. J Neurooncol 1997, 31:217-223. This paper reviews advances in the packaging systems being developed for improved gene therapy delivery.
130. Maria BL, Friedman T: Gene therapy for pediatric brain tumors. Semin Pediatr Neurol 1997, 4:333-339.
131. Kong HL, Crystal RG: Gene therapy strategies for tumor antiangiogenesis [see comments]. J Natl Cancer Inst 1998, 90:273-286.
132. Geiger T, M Mü, Dean NM, Fabbro D: Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des 1998, 13:35-45.
133. Engelhard H, Narang C, Homer R, Duncan H: Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: in vitro and in vivo studies of uptake, effects and toxicity. Biochem Biophys Res Commun 1996, 227:400-405.
134. Kondo S, Kondo Y, Li G, Silverman RH, Cowell JK: Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 1998, 16:3323-3330.
135. Nagane M, Asai A, Shibui S, Nomura K, Kuchino Y: Application of antisense ribonucleic acid complementary to O6-methylguanine-deoxyribonucleic acid methyltransferase messenger ribonucleic acid for therapy of malignant gliomas. Neurosurgery 1997, 41:434-440. Discussion. Neurosurgery 1997, 41:440-431.
136. Nagane M, Asai A, Shibui S, Nomura K, Kuchino Y: Application of antisense ribonucleic acid complementary to O6-methylguanine-deoxyribonucleic acid methyltransferase messenger ribonucleic acid for therapy of malignant gliomas. Neurosurgery 1997, 41:434-440. Discussion. Neurosurgery 1997, 41:440-431.
137. Fine HA: Novel biologic therapies for malignant gliomas, antiangiogenesis, immunotherapy, and gene therapy. Neurol Clin 1995, 13:827-846.
138. Deliganis AV, Baxter AB, Berger MS, Marcus SG, Maravilla KR: Serial MR in gene therapy for recurrent glioblastoma: initial experience and work in progress. AJNR Am J Neuroradiol 1997, 18:1401-1406.
139. Eck SL, Alavi JB, Alavi A, Davis A, Hackney D, Judy K, et al: Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. Hum Gene Ther 1996, 7:1465-1482.
140. Roy EJ, Cho BK, Rund LA, Patrick TA, Kranz DM: Targeting T cells against brain tumors with a bispecific ligand-antibody conjugate. Int J Cancer 1998, 76:761-766.
141. Ashley DM, Batra SK, Bigner DD: Monoclonal antibodies to growth factors and growth factor receptors: their diagnostic and therapeutic potential in brain tumors. J Neurooncol 1997, 35:259-273. This paper reviews the use of monoclonal antibody therapy as it relates to the manipulation of growth factors and their receptors.
142. Wersäll P, Ohlsson I, Biberfeld P, Collins VP, von Krusenstjerna S, Larsson S, et al.: Intratumoral infusion of the monoclonal antibody, Mab 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Cancer Immunol Immunother 1997, 44:157-164.
143. Miyamoto CT, Brady LW, Rackover MA, Emrich J, Class R, Bender H, et al.: The use of epidermal growth factor receptor-425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of patients with high grade gliomas of the brain. Recent Results Cancer Res 1996, 141:183-192.
144. Stragliotto G, Vega F, Stasiecki P, Gropp P, Poisson M, Delattre JY: Multiple infusions of anti-epidermal growth factor receptor [EGFR] monoclonal antibody [EMD 55,900] in patients with recurrent malignant gliomas. Eur J Cancer 1996, 32A:636-640.
145. Laske DW, Youle RJ, Oldfield EH: Tumor regression with regional distribution of the targeted toxin TF-CRM 107 in patients with malignant brain tumors [see comments]. Nat Med 1997, 3:1362-1368.
146. Rajkumar SV, Buckner JC, Schomberg PJ, Cascino TL, Burch PA, Dinapoli RP: Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma. Int J Radiat Oncol Biol Phys 1998, 40:297-302.
147. Naganuma H, Sasaki A, Satoh E, Nagasaka M, Isoe S, Nakano S, Nukui H: Long-term survival in a young patient with anaplastic glioma. Brain Tumor Pathol 1997, 14:71-74.
148. Rice CD, Baldwin NG, Biron RT, Bear HD, Merchant RE: Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction: II: cytokine production and in vivo efficacy of glioma-sensitized lymphocytes. J Neurooncol 1997, 32:29-38. This paper presents a nice example of adoptive immunotherapy for the treatment of brain tumors.
149. Plautz GE, Barnett GH, Miller DW, Cohen BH, Prayson RA, Krauss JC, et al.: Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg 1998, 89:42-51.